BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,762,343 | +105.3% | 158,107 | +146.1% | 1.11% | +156.5% |
| Q2 2023 | $5,243,421 | -16.1% | 64,234 | -23.8% | 0.43% | -24.2% |
| Q1 2023 | $6,253,104 | -56.0% | 84,285 | -50.8% | 0.57% | -60.8% |
| Q4 2022 | $14,195,686 | +140.4% | 171,280 | +724.0% | 1.46% | +76.6% |
| Q3 2022 | $5,904,000 | -17.7% | 20,787 | +0.5% | 0.82% | +8.3% |
| Q2 2022 | $7,172,000 | -20.5% | 20,690 | -0.7% | 0.76% | -4.4% |
| Q1 2022 | $9,020,000 | -71.8% | 20,830 | -66.4% | 0.80% | -71.3% |
| Q4 2021 | $32,039,000 | -3.7% | 61,930 | -9.8% | 2.77% | -6.0% |
| Q3 2021 | $33,264,000 | +2.3% | 68,647 | -4.9% | 2.95% | +16.2% |
| Q2 2021 | $32,512,000 | +10.4% | 72,207 | -6.4% | 2.54% | +1.0% |
| Q1 2021 | $29,454,000 | +90.7% | 77,120 | +58.6% | 2.51% | +39.1% |
| Q4 2020 | $15,446,000 | +54.9% | 48,640 | +20.9% | 1.81% | +80.2% |
| Q3 2020 | $9,969,000 | -39.5% | 40,240 | -35.5% | 1.00% | -36.1% |
| Q2 2020 | $16,478,000 | +32.2% | 62,400 | -5.1% | 1.57% | -9.0% |
| Q1 2020 | $12,466,000 | -5.5% | 65,741 | +9.4% | 1.72% | +13.9% |
| Q4 2019 | $13,195,000 | +55.6% | 60,111 | +38.7% | 1.51% | +103.8% |
| Q3 2019 | $8,481,000 | -21.7% | 43,345 | -16.6% | 0.74% | +2.6% |
| Q2 2019 | $10,832,000 | +33.8% | 51,956 | +27.4% | 0.72% | +14.9% |
| Q1 2019 | $8,095,000 | +1.4% | 40,770 | +4.2% | 0.63% | +56.3% |
| Q3 2018 | $7,983,000 | +7.8% | 39,110 | -21.9% | 0.40% | -34.9% |
| Q2 2018 | $7,408,000 | -46.7% | 50,070 | -45.6% | 0.62% | -63.5% |
| Q1 2018 | $13,904,000 | +52.5% | 92,052 | +30.8% | 1.70% | +32.3% |
| Q4 2017 | $9,115,000 | -6.4% | 70,362 | -12.7% | 1.28% | +5.9% |
| Q3 2017 | $9,739,000 | +13.5% | 80,560 | +10.3% | 1.21% | +30.2% |
| Q2 2017 | $8,579,000 | +61.0% | 73,010 | +40.9% | 0.93% | +94.8% |
| Q4 2016 | $5,328,000 | -38.6% | 51,815 | -34.6% | 0.48% | -55.1% |
| Q3 2016 | $8,672,000 | +21.2% | 79,200 | +24.8% | 1.06% | +12.8% |
| Q2 2016 | $7,154,000 | – | 63,440 | – | 0.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |